Literature DB >> 11283667

Therapeutic opportunities in polyglutamine disease.

R E Hughes1, J M Olson.   

Abstract

Polyglutamine diseases comprise a class of familial neurodegenerative disorders caused by expression of proteins containing expanded polyglutamine tracts. Great progress has been made in elucidating the molecular mechanisms contributing to polyglutamine pathology, and in identifying potential drug targets. Although much remains to be learned, these advances provide an opportunity for rational approaches to target-based drug discovery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283667     DOI: 10.1038/86486

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  15 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

3.  Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain-of-function mutation.

Authors:  Andrew Maselli; Ruth Furukawa; Susanne A M Thomson; Richard C Davis; Marcus Fechheimer
Journal:  Eukaryot Cell       Date:  2003-08

Review 4.  Neurodegenerative disorders: Parkinson's disease and Huntington's disease.

Authors:  S M Hague; S Klaffke; O Bandmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 5.  Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusions.

Authors:  Lyne Jossé; Ricardo Marchante; Jo Zenthon; Tobias von der Haar; Mick F Tuite
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

6.  Genomics analysis of genes expressed in maize endosperm identifies novel seed proteins and clarifies patterns of zein gene expression.

Authors:  Y M Woo; D W Hu; B A Larkins; R Jung
Journal:  Plant Cell       Date:  2001-10       Impact factor: 11.277

Review 7.  The spinocerebellar ataxias: order emerges from chaos.

Authors:  Russell L Margolis
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

8.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

Review 9.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

Review 10.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.